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Background & aims: The effect of vitamin D on lipid proﬁle in type 2 diabetic patients is controversial.
This meta-analysis aimed to assess the effect of vitamin D on serum total cholesterol (TC), triglycerides
(TG), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) of these patients to elucidate
the subject.
Methods: Seven databases were searched and randomized controlled trials (RCTs) assessed the effect of
vitamin D on lipid proﬁle published until November 2015 were identiﬁed. Un-standardized mean dif-
ference and its corresponding 95% conﬁdence interval (CI) was calculated from the effect sizes by using
random effects model.
Results: We found 2220 articles in our systematic search, after exclusion of un-related studies we
enrolled 17 studies comparing intervention group (received vitamin D) with control group (received
placebo) in the meta-analysis. Vitamin D signiﬁcantly reduced serum TC (3.74 mg/dl, 95% CI: 7.13
to 0.34, P ¼ 0.031), but serum TG did not show signiﬁcant reduction (4.90 mg/dl, 95% CI: 15.11e5.31,
P ¼ 0.347). Results conﬁrmed the signiﬁcant lowering effect of vitamin D on LDL in patients with T2D
(2.55 mg/dl, 95% CI: 4.83 to 0.26, P ¼ 0.029), but change in serum HDL was negligible (0.72 mg/dl,
95% CI: 1.27 to 0.17, P ¼ 0.010). Subgroup analyses showed that the baseline serum 25-hydroxy
vitamin D of patients, vitamin D dosage, intervention duration, and the method of vitamin D applica-
tion inﬂuence the effect of vitamin D on lipid markers.
Conclusion: This study demonstrated that vitamin D improved serum levels of TC, TG, and LDL in patients
with T2D but changes of serum HDL was not satisfactory.
© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Type 2 diabetes (T2D) is one of themain causes of morbidity and
mortality throughout the world. It is estimated that up to 2035,
more than 600 million patients would suffer from the disease [1].
The related annual therapeutic and rehabilitative costs of diabetes
are onerous. A great deal of the health-related expenditures are
dedicated to diabetes and its complications [2].
Vitamin D was discovered in 1928 and for years was known as
an essential factor for bone growth and calcium homeostasis.try and Nutrition, Faculty of
ces, Shahrekord, Iran. Tel./
for Clinical Nutrition and MetabolBeyond the skeletal effects, the presence of vitamin D receptors in
other tissues and organs illustrates its extra-skeletal effects like
modulation of immune function and inﬂammation, insulin secre-
tion, cardiovascular protection, and gene expression [3,4].
Vitamin D deﬁciency and insufﬁciency as a worldwide problem
is related to chronic diseases such as diabetes, metabolic syndrome,
and cardiovascular diseases [3,5]. Serum levels of 25-hydroxy
vitamin D (25OHD) is used to determine the vitamin D status.
Themost acceptable deﬁnition introduced by the Endocrine Society
states Serum levels of 25OHD <50, 50e74, and >75 nmol/l as
deﬁcient, insufﬁcient, and sufﬁcient, respectively [6].
It is demonstrated that low-grade inﬂammation and auto-
immune activation play important roles in development and pro-
gression of T2D. Increased activity of inﬂammatory cytokines in-
duces beta-cell apoptosis in the pancreas and increases insulinism. All rights reserved.
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betes. Regarding anti-inﬂammatory effects of vitamin D and the
fact that diabetes is more prevalent in vitamin D deﬁcient subjects,
vitamin D has been used in clinical trials for diabetic patients
[3,7,8]. Cardiovascular events are common problem in diabetic
subjects and as one of the major causes of morbidity and mortality
require precise interventions. Dyslipidemia is known as a potential
risk factor for cardiovascular events andmust be managed carefully
[9]. Dyslipidemia is also common in patients with T2D. Moreover,
observational studies declared that subjects with high serum
25OHD have acceptable levels of lipid markers [10].
The effect of vitamin D on lipid proﬁle of diabetic patients is
considered in some clinical trials; however, the results are contro-
versial. Thismeta-analysis aimed to assess the effect of vitamin D on
lipid proﬁle of patients with T2D to elucidate the subject.
2. Materials and methods
2.1. Review design and search strategy
The protocol was registered in PROSPERO, the international
database of registered systematic reviews (registration number:
CRD42015027867). The PRISMA guidelines were followed for per-
forming and reporting the results of this meta-analysis [11]. Seven
databases including PubMed, Cochrane register of control trials, ISI
Web of Science, Scopus, Google Scholar, Magiran, and Iran Medex
were searched and randomized controlled trials (RCTs) published
until November 2015 were identiﬁed.
Pubmed was searched with the search strategy as follows:
(”Cholecalciferol“[Mesh] OR ”Calcitriol“[Mesh] OR ”Vitamin
D“[Mesh] OR ”Ergocalciferols“[Mesh] OR “vitamin D2”[tiab] OR
“vitamin D3”[tiab] OR “vitamin D-”) AND (”Diabetes Melli-
tus“[Mesh] OR ”Diabetes Mellitus, Type 2“[Mesh] OR “type 2 dia-
betes”[tiab] OR “diabetic”[tiab] OR “diabetes”[tiab]) AND
(”Intervention Studies“[MESH] OR ”intervention“[tiab] OR
”controlled trial“[tiab] OR ”randomized“[tiab] OR ”random-
ised“[tiab] OR ”random“[tiab] OR ”randomly“[tiab] OR ”placebo“[-
tiab] OR ”assignment“[tiab] OR ”clinical trial“[All Fields] OR
”trial“[All Fields]). The search strategy for ISI Web of Science was:
(”Cholecalciferol“ OR ”Calcitriol“ OR ”Vitamin D“ OR ”Ergocalcifer-
ols“ OR “vitamin D2” OR “vitamin D3” OR “vitamin D-”) AND
(”Diabetes Mellitus“ OR ”Diabetes Mellitus, Type 2“ OR “type 2
diabetes” OR “diabetic” OR “diabetes”) AND (”Intervention Studies“
OR ”intervention“ OR ”controlled trial“ OR ”randomized“ OR
”randomised“ OR ”random“ OR ”randomly“ OR ”placebo“ OR
”assignment“ OR ”clinical trial“ OR ”trial“). Scopus was searched
with: ”Cholecalciferol“ OR ”Calcitriol“ OR ”Vitamin D“ OR ”Ergo-
calciferols“ OR ”vitamin D2“ OR ”vitamin D3“ OR ”vitamin D-“ AND
”Diabetes Mellitus“ OR ”Diabetes Mellitus, Type 2“ OR ”type 2
diabetes“ OR ”diabetic“ OR ”diabetes“ AND ”Intervention Studies”.
The other databases were searched by the key words: “vitamin D”
AND “diabetes”. Titles, abstracts, and if necessary full text of the
studies were separately evaluated by authors to identify the related
studies. Moreover, a hand-search was performed on references of
selected studies to avoid missing the RCTs.
2.2. Study selection
The eligibility criteria to select the studies were parallel-group
RCTs in which consumption of a kind of vitamin D (as supplement
or fortiﬁed food) was compared with placebo in patients with T2D.
Studieswith participants in any levels of baseline serum25OHDwere
included. All kinds of vitamin D like vitamin D2 (ergocalciferol),
vitaminD3 (cholecalciferol), calcitriol (1, 25-hydroxyvitaminD3),1-a-
hydroxylated versions of vitamin D, paricalcitol, and doxerocalciferolused for intervention were also considered. Studies used co-
supplementation were included if the control group did not receive
anyotherkindofco-supplementation.StudiesusedvitaminDonnon-
type 2 diabetic or pre-diabetic subjects or diabetic patients with ne-
phropathywere excluded. Themeta-analyses outcomewere changes
from baseline in serum lipid proﬁle (total cholesterol (TC), Low-
density lipoprotein (LDL), high-density lipoprotein (HDL), and tri-
glycerides (TG)) after the follow up period.
2.3. Quality assessment
The quality of selected RCTs was assessed by modiﬁed Jadad
score [12]. The intention-to-treat and use of blinded endpoints
were also added [13]. The score 1 for “Yes” and 0 for “No” were
assigned to each answer; so the range of new scoring system was
between 0 and 7. This assessment was used to clarify the probable
heterogeneity in the results and to achieve a more speciﬁc and
precise deductions.
The Grades of Recommendation, Assessment, Development, and
Evaluation (GRADE) system was used to evaluate the quality of
evidence for each outcome (GRADE pro software version 3.6). The
quality of evidence was classiﬁed as high, moderate, and low [14].
2.4. Extraction of data
The quality scores and characteristics of selected RCTs
comprising number of subjects, vitamin D dose (international unit
per day), method of vitamin D application, intervention duration,
co-supplementation, mean serum 25OHD (nmol/l) of the subjects
are shown in Table 1. To increase the precision, the data was
extracted independently by the authors. The longest duration of the
interventions was considered. For studies with several vitamin D
doses, each dose was considered separately if possible.
2.5. Statistical analyses
Cohenʼs Kappa statistic was used to assess the inter-reviewers
agreement in ﬁnding the studies, data extraction, and quality
assessment [15,16]. Effect size was extracted from each study using
mean and standard deviation for TC, LDL, HDL, and TG before and
after the intervention. Un-standardized mean difference and its
corresponding 95% conﬁdence interval (CI) was calculated from the
effect sizes by using random effects model [17]. Lipid markers were
reported in mg/dl. Subgroup analyses were performed based on
baseline serum 25OHD, method of vitamin D application, vitamin D
doses, and intervention duration. Inﬂuence analysis was also used
to explore the possible sources of heterogeneity among the studies.
The heterogeneity was statistically estimated using Cochran's Q test
[18] and I-squared (I2) value (ranged from 0 to 100%) [19,20]. The
values  25%, 26e50% and >50% are referred to low, moderate, and
high estimates, respectively. The funnel plot, Begg and Mazumdar
rank correlation test and Egger test were used to evaluate the
publication bias [21]. Statistical analyses were carried out using
Stata version 11.2 (Stata Corp, College Station, TX). The differences
were considered signiﬁcant at P  0.05.
3. Results
3.1. Study selection and identiﬁcation
The study selection process is shown in Fig. 1. We found 2220
articles in our systematic search; 697 duplicated records were
excluded. After reading the titles and abstracts, 1465 from 1523
records were also excluded because of their irrelevancy to the
subject. We identiﬁed 58 articles that went through detailed
T. Jafari et al. / Clinical Nutrition 35 (2016) 1259e1268 1261inspection to ﬁnd the studies assessing the effects of vitamin D on
serum lipid proﬁle. Therefore, 35 articles were excluded and the
remaining 23 studies were found to be relevant to the topic. Finally,
we enrolled 17 studies in our meta-analysis comparing interven-
tion group (received vitamin D) with control group (received pla-
cebo) and excluded 6 records; ﬁve studies had not a control group
and 1 study had not report the results.
We enrolled the study of Witham et al. [22] (with 2 different
vitamin D doses) as 2 different studies, as well as the studies of
Nikooyeh et al. [23], and Tabesh et al. [24] (both had an additional
intervention group for vitamin D and calcium co-supplementation)
which were considered as 2 different studies. Therefore, 20 studies
were considered in the meta-analysis. In most studies, participants
had baseline serum level of 25OHD <50 nmol/l; however, it raised
to >50 nmol/l after the interventions (Table 1).
The agreement percentages among researchers and Cohen's
Kappa coefﬁcients in ﬁnding the studies, data extraction, and
quality assessment of the selected studies were >85% and between
0.8 and 1, respectively, which demonstrates a favorable agreement
between inter-reviewers.
3.2. Outcomes analysis
The summary of ﬁndings table (Table S1) shows the quality
assessment for each outcome. “High” implied that further research
is doubtful to change the conﬁdence of estimated effect. “Moder-
ate” implied that further research is likely to have an important
effect on the conﬁdence of estimated effect. “Low” implied that
further research will probably change the conﬁdence of estimated
effect.
3.3. Effect of vitamin D on serum TC
All the studies including 1365 subjects had data on the effect of
vitamin D on serum TC [3,22e37]. Results demonstrated thatTable 1
Characteristics of randomized controlled trials enrolled in the meta-analyses.
Study/year Quality
scorea
No. of
subjects
Vitamin D dose (IU/
day)
Method
applicat
Jafari et al., 2016 [3] 5 59 2000 Fortiﬁca
Witham et al., 2010 [22] 5 40 833.33 Supplem
Witham et al., 2010 [22] 5 39 1666.67 Supplem
Nikooyeh et al., 2011 [23] 5 60 1000 Fortiﬁca
Nikooyeh et al., 2011 [23] 5 60 1000 Fortiﬁca
Tabesh et al., 2014 [24] 5 59 7142.86 Supplem
Tabesh et al., 2014 [24] 5 60 7142.86 Supplem
Kim et al., 2008 [25] 3 24 1200 Supplem
Jorde et al., 2009 [26] 2 32 5714.28 Supplem
Shab-Bidar et al., 2011 [27] 5 100 1000 Fortiﬁca
Munoz-Aguirre et al., 2015
[28]
6 104 4000 Supplem
Shehab et al., 2015 [29] 2 112 7142.86 Supplem
Breslavsky et al., 2013 [30] 2 46 1000 Supplem
Youseﬁ Rad et al., 2014 [31] 3 58 4000 Supplem
Yiu et al., 2013 [32] 5 100 5000 Supplem
Al-Zahrani et al., 2014 [33] 3 183 6428.57 Supplem
Eftekhari et al., 2014 [34] 3 70 20 Supplem
Kampmann et al., 2014 [35] 4 15 6500 Supplem
Ryu et al., 2014 [36] 5 62 2000 Supplem
Sadiya et al., 2014 [37] 5 82 4500 Supplem
a Quality score of the studies was assessed by Jadad score.
b Defﬁcient, serum 25OHD <50 nmol/l; insufﬁcient, 50  serum 25OHD <75 nmol/l; svitamin D signiﬁcantly reduced TC (11.67 mg/dl, 95% CI: 19.78
to 3.55, P¼ 0.005, data not shown). There was no publication bias
by Beggʼs funnel plot and Egger's test (Eggerʼs test P ¼ 0.897). The
between studies heterogeneity was high according to I2 (97.1%) and
Cochrane Q tests (P < 0.001). Inﬂuence analysis was carried out to
ﬁnd the sources of heterogeneity. Results demonstrated that most
of the heterogeneity belonged to the studies of Tabesh et al. [24],
Rad et al. [31], and Eftekhari et al. [34]. We, therefore, re-analyzed
the data after exclusion of the mentioned studies. The heteroge-
neity among the studies was clearly reduced (I2 ¼ 30.1%, P ¼ 0.123)
and the results demonstrated that vitamin D signiﬁcantly reduced
serum TC (Fig. 2: 3.74 mg/dl, 95% CI: 7.13 to 0.34, P ¼ 0.031).
Subgroup analyses were also performed based on baseline
serum 25OHD of participants, method of vitamin D provision
(supplementation or food fortiﬁcation), vitamin D dosage, and
intervention duration (Table 2). Vitamin D signiﬁcantly reduced
serum TC in subjects with baseline serum levels of
25OHD 50 nmol/l. Serum TC did not show signiﬁcant reduction in
vitamin D deﬁcient subjects (2.39 mg/dl, 95% CI: 8.84e4.06,
P ¼ 0.467). Vitamin D-fortiﬁed foods signiﬁcantly reduced serum
TC (7.31 mg/dl, 95% CI: 14.23 to 0.39, P ¼ 0.038), while the
result of vitamin D supplementation was not statistically signiﬁ-
cant. Regarding the dose and the duration of intervention, vitamin
D in doses 2000 IU per day and in the duration of >12 weeks
signiﬁcantly reduced serum TC in patients with T2D (Table 2).
3.4. Effect of vitamin D on serum TG
The effect of vitamin D on serum TG was assessed in 17 studies
with 1271 participants [3,23e34,36,37]. Results showed that
vitamin D signiﬁcantly reduced TG in type 2 diabetic patients
(9.49 mg/dl, 95% CI: 18.86 to 0.12, P ¼ 0.047, data not shown).
Begg's funnel plot and Egger's test indicated that there was no
publication bias among the studies (Egger's test P ¼ 0.536). The
between studies heterogeneity was high according to I2 (85.2%) andof
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Fig. 1. PRISMA ﬂow diagram of study identiﬁcation, inclusion, and exclusion.
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Figure 2 Forest plot of the effect of vitamin D on total cholesterol
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Fig. 2. Forest plot of the effect of vitamin D on total cholesterol.
T. Jafari et al. / Clinical Nutrition 35 (2016) 1259e1268 1263Cochrane Q tests (P < 0.001). Inﬂuence analysis revealed that the
heterogeneity speciﬁcally belonged to the studies mentioned
before [24,31,34]. After the exclusion of the studies, the heteroge-
neity was signiﬁcantly reduced (I2 ¼ 24.6% and Cochrane Q test
P ¼ 0.195) but the lowering effect of vitamin D on serum TG con-
centration was not statistically signiﬁcant (Fig. 3: 4.90 mg/dl, 95%
CI: 15.11e5.31, P ¼ 0.347).
Subgroup analyses indicated that serum TG reduced signiﬁ-
cantly in type 2 diabetic patients who received vitamin
D  2000 IU/d (19.02, 95% CI: 31.04 to 6.99, P ¼ 0.002).
Vitamin D-fortiﬁed foods also signiﬁcantly reduced the serum TG
(4.90, 95% CI: 15.11 to 5.31, P ¼ 0.006); however, the effect of
vitamin D on TG did not depend on the baseline serum 25OHD or
the duration of vitamin D administration for these patients
(Table 3).Table 2
Results of the effect of vitamin D on total cholesterol based on subgroup analyses.
Variable No. of trials Effect size (95%C
Baseline serum 25OHDa
Defﬁcient (<50 nmol/l) 9 2.39 (8.84, 4.
Insufﬁcient (50e75 nmol/l) 5 3.74 (7.26, 0
Sufﬁcient (>75 nmol/l) 2 13.01 (23.90,
Method of vitamin D applicationa
Supplementation 12 2.51 (6.55, 1.
Food fortiﬁcation 4 7.31 (14.23, 
Vitamin D dosagea
2000 IU/day 9 6.19 (11.57, 
>2000 IU/day 7 1.82 (6.16, 2.
Intervention durationa
12 weeks 9 3.22 (7.75, 1.
>12 weeks 7 4.97 (10.43, 0
a Analyses done without the studies of Tabesh et al. [24], Rad et al. [31], and Eftekhar3.5. Effect of vitamin D on serum LDL
The meta-analysis of 18 studies with 1286 participants
demonstrated that vitamin D did not signiﬁcantly reduce the LDL
(4.77 mg/dl, 95% CI: 13.78e4.24, P ¼ 0.300, data not shown).
No publication bias found using Beggʼs funnel plot and Egger's
test (Eggerʼs test P ¼ 0.222). However, the between studies
heterogeneity was high according to I2 (98.3%) and Cochrane Q
tests (P < 0.001). Inﬂuence analysis revealed that the heteroge-
neity belonged to the study of Tabesh et al. [24]. After exclusion
of that study, the heterogeneity was signiﬁcantly reduced
(I2 ¼ 26.5% and Cochrane Q test P ¼ 0.156) and results conﬁrmed
the signiﬁcant lowering effect of vitamin D on LDL in patients
with T2D (Fig. 4: 2.55 mg/dl, 95% CI: 4.83 to 0.26,
P ¼ 0.029).I) mg/dl P Value I2 (%) Q-statistics (P)
06) 0.467 53.2 0.029
.23) 0.037 0 0.975
2.12) 0.019 0 0.781
53) 0.223 30.3 0.150
0.39) 0.038 32.2 0.219
0.80) 0.024 30.4 0.175
52) 0.411 28.3 0.212
30) 0.162 42.5 0.084
.48) 0.074 13.5 0.327
i et al. [34].
Fig. 3NOTE: Weights are from random effects analysis
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Fig. 3. Forest plot of the effect of vitamin D on triglycerides.
T. Jafari et al. / Clinical Nutrition 35 (2016) 1259e12681264Subgroup analyses showed that vitamin D signiﬁcantly reduced
LDL in type 2 diabetic patients with baseline serum levels of
25OHD 50 nmol/l. Administration of vitamin D for 12 weeks or
less signiﬁcantly reduced the serum LDL in the patients (3.09, 95%
CI: 5.20 to 0.98, P ¼ 0.004). According to the subgroup analyses,
vitamin D dose or method of its application did not signiﬁcantly
reduce serum LDL (Table 4).
3.6. Effect of vitamin D on serum HDL
The meta-analysis of 18 RCTs with 1286 type 2 diabetic patients
showed that vitamin D did not signiﬁcantly change serum HDL in
patients with T2D (1.92 mg/dl, 95% CI: 2.45e6.29, P ¼ 0.390, data
not shown). There was no publication bias found by Beggʼs funnelTable 3
Results of the effect of vitamin D on triglycerides based on subgroup analyses.
Variable No. of trials Effect size (95%C
Baseline serum 25OHDa
Defﬁcient (<50 nmol/l) 9 12.29 (26.30,
Insufﬁcient (50e75 nmol/l) 4 2.94 (9.08, 14.9
Sufﬁcient (>75 nmol/l) 0 e
Method of vitamin D applicationa
Supplementation 9 6.24 (4.60, 17.0
Food fortiﬁcation 4 4.90 (15.11, 
Vitamin D dosagea
2000 IU/day 7 19.02 (31.05,
>2000 IU/day 6 9.59 (1.80, 20.9
Intervention durationa
12 weeks 8 7.49 (21.13, 6
>12 weeks 5 1.74 (19.31, 22
a Analyses done without the studies of Tabesh et al. [24], Rad et al. [31], and Eftekharplot and Egger's test (Eggerʼs test P ¼ 0.360). The between studies
heterogeneity was high according to I2 (98.8%) and Cochrane Q tests
(P < 0.001). Inﬂuence analysis revealed that the heterogeneity
belonged to the study of Tabesh et al. [24]. The analysis was re-
performed after excluding that study, showing that vitamin D
slightly but signiﬁcantly decreased the serum HDL
(Fig. 5: 0.72 mg/dl, 95% CI: 1.27 to 0.17, P ¼ 0.010). The het-
erogeneity was also signiﬁcantly reduced (I2 ¼ 0% and Cochrane Q
test P ¼ 0.765).
Subgroup analyses showed that vitamin D supplementation
decreased the serum HDL in type 2 diabetic patients with sufﬁcient
serum levels of 25OHD (1.20, 95% CI: 1.95 to 0.44, P ¼ 0.002),
particularly when the intervention durationwas12 weeks (0.71,
95% CI: 1.33 to 0.083, P ¼ 0.026). However, vitamin D-fortiﬁedI) mg/dl P Value I2 (%) Q-statistics (P)
1.85) 0.089 20.9 0.257
7) 0.631 5.00 0.368
e e e
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.78) 0.871 0 0.827
i et al. [34].
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Fig. 4. Forest plot of the effect of vitamin D on LDL.
T. Jafari et al. / Clinical Nutrition 35 (2016) 1259e1268 1265food improved serum HDL in these patients but the results was not
statistically signiﬁcant (Table 5).4. Discussion
Diabetes-related dyslipidemia (hypertriglyceridemia, low-
serum HDL, elevated serum TC, and cholesterol-rich lipoproteins)
is prevalent and can lead to atherosclerosis. Statins are the most
common drugs used for treatment of these disorders in patients
with T2D. However, the problem may have been incompletely
resolved, so the adjuvant therapies are required as well.Table 4
Results of the effect of vitamin D on LDL cholesterol based on subgroup analyses.
Variable No. of trials Effect size (95%C
Baseline serum 25OHDa
Defﬁcient (<50 nmol/l) 10 0.40 (3.81, 3.
Insufﬁcient (50e75 nmol/l) 5 4.85 (8.73, 0
Sufﬁcient (>75 nmol/l) 1 4.30 (6.63, 1
Method of vitamin D applicationa
Supplementation 12 2.01 (4.44, 0.
Food fortiﬁcation 4 5.61 (12.00, 0
Vitamin D dosagea
2000 IU/day 8 2.13 (6.94, 2.
>2000 IU/day 8 1.68 (3.97, 0.
Intervention durationa
12 weeks 11 3.09 (5.20, 0
>12 weeks 5 0.68 (6.31, 7.68
a Analyses done without the study of Tabesh et al. [24].Obvious correlations are reported between higher levels of
serum 25OHD and lower prevalence of diabetes, hypertension and
cardiovascular diseases [3]. Observational studies reported an in-
verse correlation between higher levels of serum 25OHD and lower
levels of total serum cholesterol, LDL, TG, and higher levels of serum
HDL [10]; but the results of RCTs to evaluate the effects of vitamin D
on lipid proﬁle are conﬂicting. The exact mechanism by which
vitamin D affects lipid markers is not clear.
The overall results of the current meta-analyses revealed that
vitamin D improved serum levels of TC, TG, and LDL, while changes
in serum HDL were negligible. It could be estimated that serum TC
of type 2 diabetic patients received vitamin D, reduce about 4 mg/I) mg/dl P Value I2 (%) Q-statistics (P)
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Table 5
Results of the effect of vitamin D on HDL cholesterol based on subgroup analyses.
Variable No. of trials Effect size (95%CI) mg/dl P Value I2 (%) Q-statistics (P)
Baseline serum 25OHDa
Defﬁcient (<50 nmol/l) 10 0.13 (1.17, 0.90) 0.800 0 0.776
Insufﬁcient (50e75 nmol/l) 5 0.27 (1.52, 0.97) 0.665 0 0.780
Sufﬁcient (>75 nmol/l) 1 1.20 (1.95, 0.44) 0.002 0 0
Method of vitamin D applicationa
Supplementation 12 0.93 (1.50, 0.35) 0.001 0 0.996
Food fortiﬁcation 4 1.46 (0.40, 3.33) 0.125 0 0.454
Vitamin D dosagea
2000 IU/day 8 0.09 (1.34, 1.53) 0.897 28.8 0.198
>2000 IU/day 8 0.60 (1.50, 0.31) 0.195 0 0.997
Intervention durationa
12 weeks 11 0.71 (1.33, 0.083) 0.026 3.40 0.410
>12 weeks 5 0.16 (2.01, 1.69) 0.865 0 0.999
a Analyses done without the study of Tabesh et al. [24].
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achieved when baseline serum levels of 25OHD was >75 nmol/l
(~13 mg/dl reduction); hence serum levels of 25OHD > 75 nmol/l
might be optimal to have beneﬁcial effect on serum TC. It is also
suggested that administration of vitamin D  2000 IU per day is
enough to reduce serum TC (~6 mg/dl reduction). The effects of
vitamin D on serum TC seems to be more effective in subjects who
received a vitamin D-fortiﬁed food than those who received sup-
plements. Pooling the data from RCTs demonstrated that vitamin D
administration for a mean period of 12 weeks, reduced serum LDL
(~3e4 mg/dl) in type 2 diabetic patients with baseline serum levels
of 25OHD > 50 nmol/l.
The serum TC concentration is affected by cholesterol absorp-
tion from the gut and endogenous biosynthesis of cells. Changes inserum campesterol and lathosterol as cholesterol precursors,
indicate the amount of cholesterol absorption and endogenous
production, respectively. The possible role of vitamin D on intesti-
nal cholesterol absorption or endogenous production is not clear
and needs further investigations. Kane et al. [38] reported the
reduction of serum campesterol in statin-treated subjects who
received vitamin D. They suggested that vitamin D might reduce
intestinal cholesterol absorption. Vitamin D can also prevent
atherosclerosis by reduction of foam cell formation and decrease
LDL deposition in macrophages of patients with T2D [39].
It has been demonstrated that vitamin D increases lipoprotein
lipase (LPL) gene expression in muscles and adipose tissue. The
activation of LPL increases the clearance of circulating lipoprotein
particles and modiﬁes the lipid proﬁle in favor of reducing
T. Jafari et al. / Clinical Nutrition 35 (2016) 1259e1268 1267atherosclerosis. The most obvious effects of LPL are reduction in
serum TG and increase in serum HDL [40]. Hypertriglyceridemia,
low serum HDL, and decreased adipose tissue LPL activity are
common in diabetic patients. Therefore, vitamin D administration
could have beneﬁts for these subjects. Although pooling the data
from RCTs showed that vitamin D did not signiﬁcantly reduce
serum TG, subgroup analyses demonstrated that administration of
vitamin D  2000 IU per day signiﬁcantly reduced serum TG
(~19 mg/dl) in patients with T2D. Patients consuming a vitamin D-
fortiﬁed food showed the best results, which might be because
those taking supplements had been advised to take them with fat
containing foods, to improve its absorption.
Our meta-analysis found a very slight but signiﬁcant decrease in
serum HDL (<1 mg/dl) in type 2 diabetic patients who received
vitamin D. Subjects with sufﬁcient baseline serum vitamin D, or
those who received vitamin D as supplements for 12 weeks or less,
even showed detrimental results (~1 mg/dl reduction). More
studies on vitamin D-deﬁcient patients with longer durations are
needed to clarify these results. As mentioned before, it seems that
vitamin D can increase serum HDL by activating the LPL, but other
mechanisms by which vitamin D affects serum HDL are not clear.
Studies in vitamin D-receptor knockout mice revealed higher HDL
and hepatic apo A-1 mRNA expression compare to wild type.
Vitamin D experimental studies on cultured hepatocytes supported
these ﬁndings [41]. But human studies have conﬂicting results; a
positive relationship between plasma apo A-1 and HDL is reported
with serum 25OHD, while in the small intestine and hepatocytes an
inverse association is suggested [42].
The current meta-analyses demonstrate that, overall, vitamin D-
fortiﬁcation has more desirable effect on lipid proﬁle in patients
with T2D comparing to vitamin D-supplementation. Considering
the fact that diabetic patients usually used a great deal of medi-
cines, the compliance of subjects receiving vitamin D as a fortiﬁed
foodmay be better than that of those given vitamin D supplements.
It is also represented that vitamin D  2000 IU/day and in an
intervention duration of 12 weeks have more beneﬁcial effects on
lipid proﬁle compare to higher doses and longer durations.
Considering the possible role of vitamin D as an adjuvant treatment
for dyslipidemia, it may be due to the fact that patients were not in
the same levels of lipid control.
Inﬂuence analyses indicated that the major sources of hetero-
geneity in results were due to studies of Tabesh et al. [24], Eftekhari
et al. [34], and Rad et al. [31]. We decided to conduct the meta-
analyses after the exclusion of the mentioned studies. The other
sources of heterogeneity were the variations in the study popula-
tion, geographical latitudes, gender, the health status of patients,
and quality of the studies. We also performed subgroup analyses to
represent the effect of vitamin D on lipid markers more clearly.
Wang et al. [10] conducted a meta-analysis to evaluate the effect
of vitamin D on lipid proﬁle of subjects with different health con-
ditions. They concluded that vitamin D supplementation increased
LDL, but does not signiﬁcantly affect serum TC, HDL, and TG. Our
different results might be due to the fact that we just evaluate type
2 diabetic patients. It is also possible that lipid-lowering effects of
vitamin D were different based on the study population and might
be seen more apparently in patients with metabolic disorders such
as diabetes and cardiovascular diseases as well as having hyper-
cholesterolemia or other abnormal lipid metabolism.
According to GRADE, all lipid markers as outcomes were
appraised as moderate quality. It means that further research may
change the estimated effects. Some strengths of the current study
are as follows: the design of the study, conducting the analyses on a
speciﬁc population (type 2 diabetic subjects) instead of pooling
populations with different health conditions, and subgroup ana-
lyses. This study is the ﬁrst meta-analysis assessing the effect ofvitamin D on lipid proﬁle in patients with T2D. There are also some
limitations: evaluating the effects of vitamin D with calcium co-
supplementation on lipid markers was not possible due to the
small number of studies on the subject, lipid markers had been
assessed by methods with different accuracy, patients might have
been in different status of diabetes, and the history of using anti-
dyslipidemic drugs (such as statins) was not clear.
5. Conclusion
This study demonstrated that vitamin D had minor effects on
lipid proﬁle of type 2 diabetic patients. Therefore, vitamin D cannot
be considered as a main therapeutic agent for dyslipidemia, but it
could be used as an adjuvant therapy along with the other treat-
ments for those patients. Vitamin D dosage and the duration of
interventionmight inﬂuence the effect of vitamin D on lipid proﬁle.
Type 2 diabetic patients with different baseline serum 25OHD
showed different results. The current meta-analyses also demon-
strated that vitamin D-fortiﬁcation has more desirable effect on
lipid proﬁle of patients with T2D, as compared to the vitamin D-
supplementation.
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